Recently, Lee et al. [315] showed that calebin-A has anticancer potential in peripheral nerve sheath tumor cells by inhibiting the proliferation of MPNST and primary neurofibromas in a dose-dependent manner, by increasing the population in the G0/G1 phase, and by reducing the expression of phosphorylated-AKT, -ERK1/2, survivin, hTERT, acetyl H3 proteins, the promoter DNA copies of survivin (BRIC5), the hTERT genes, and the enzymatic activity of HAT without affecting that of HDAC [315]. The gene discussed is MAPK3; the disease is neurofibroma.